|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LINC01473 |
Gene summary for LINC01473 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LINC01473 | Gene ID | 101927217 |
| Gene name | long intergenic non-protein coding RNA 1473 | |
| Gene Alias | LINC01473 | |
| Cytomap | 2q32.1 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 101927217 | LINC01473 | CCI_1 | Human | Cervix | CC | 3.50e-08 | 4.25e-01 | 0.528 |
| 101927217 | LINC01473 | CCI_3 | Human | Cervix | CC | 1.09e-21 | 8.41e-01 | 0.516 |
| 101927217 | LINC01473 | AEH-subject1 | Human | Endometrium | AEH | 2.94e-11 | 3.81e-01 | -0.3059 |
| 101927217 | LINC01473 | AEH-subject2 | Human | Endometrium | AEH | 4.68e-08 | 4.01e-01 | -0.2525 |
| 101927217 | LINC01473 | AEH-subject3 | Human | Endometrium | AEH | 2.28e-08 | 3.09e-01 | -0.2576 |
| 101927217 | LINC01473 | AEH-subject4 | Human | Endometrium | AEH | 2.32e-04 | 3.25e-01 | -0.2657 |
| 101927217 | LINC01473 | AEH-subject5 | Human | Endometrium | AEH | 2.16e-17 | 5.65e-01 | -0.2953 |
| 101927217 | LINC01473 | EEC-subject1 | Human | Endometrium | EEC | 3.81e-12 | 3.90e-01 | -0.2682 |
| 101927217 | LINC01473 | EEC-subject2 | Human | Endometrium | EEC | 1.18e-09 | 3.62e-01 | -0.2607 |
| 101927217 | LINC01473 | EEC-subject4 | Human | Endometrium | EEC | 3.36e-10 | 3.61e-01 | -0.2571 |
| 101927217 | LINC01473 | EEC-subject5 | Human | Endometrium | EEC | 9.32e-13 | 3.96e-01 | -0.249 |
| 101927217 | LINC01473 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.08e-03 | -8.10e-02 | -0.1916 |
| 101927217 | LINC01473 | RNA-P17T-P17T-4 | Human | Lung | IAC | 1.13e-06 | 7.88e-01 | 0.343 |
| 101927217 | LINC01473 | RNA-P17T-P17T-6 | Human | Lung | IAC | 1.13e-06 | 7.29e-01 | 0.3385 |
| 101927217 | LINC01473 | RNA-P17T-P17T-8 | Human | Lung | IAC | 1.77e-07 | 6.59e-01 | 0.3329 |
| 101927217 | LINC01473 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 1.19e-15 | 6.64e-01 | -0.2116 |
| 101927217 | LINC01473 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 3.94e-06 | 5.50e-01 | -0.1941 |
| 101927217 | LINC01473 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 7.22e-04 | 4.80e-01 | -0.2107 |
| 101927217 | LINC01473 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.31e-08 | 5.16e-01 | -0.2119 |
| 101927217 | LINC01473 | RNA-P3T-P3T-1 | Human | Lung | IAC | 1.03e-03 | 4.12e-01 | 0.1829 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Cervix | N_HPV |  |
| Endometrium | AEH |  |
| Endometrium | EEC |  |
| Prostate | BPH |  |
| Prostate | Tumor |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |